老年淋巴瘤患者大剂量化疗联合自体造血干细胞移植的毒性研究
该研究比较了60-69岁与≥70岁淋巴瘤患者接受BEAM方案联合自体造血干细胞移植的毒性,发现多数患者出现严重毒性,≥70岁组心血管和皮肤毒性风险更高,且非复发死亡率更高,调整早期严重毒性数量后进展或死亡风险仍升高。
要点
- 老年淋巴瘤患者BEAM+AHCT后严重毒性常见,以中性粒细胞缺乏伴发热、胃肠道、感染和心血管毒性为主
- ≥70岁患者≥3级心血管毒性风险是60-69岁组的3.36倍,皮肤毒性风险为2.45倍
- ≥70岁组100天和2年非复发死亡率分别为2.99%和6.2%,高于60-69岁组的1.79%和2.91%
核心结论
- BEAM方案联合自体造血干细胞移植在老年淋巴瘤患者中有效,但伴随显著的器官毒性,尤其是≥70岁患者。
- 迫切需要干预措施以减轻毒性并保持疗效。
研究设计与样本
- 回顾性研究,纳入346例接受BEAM联合自体造血干细胞移植的淋巴瘤患者,分为60-69岁组(279例)和≥70岁组(67例)。
主要发现
- 多数患者发生严重毒性,最常见为中性粒细胞缺乏伴发热、胃肠道毒性、感染和心血管毒性。
- ≥70岁组≥3级心血管毒性风险显著高于60-69岁组(HR 3.36,95%CI 2.25-5.00,P<.001)。
- ≥70岁组≥3级皮肤毒性风险显著高于60-69岁组(HR 2.45,95%CI 1.08-5.54,P=.032)。
- ≥70岁组100天非复发死亡率为2.99%(95%CI 0.55-9.32),2年非复发死亡率为6.2%(95%CI 1.97-13.95);60-69岁组分别为1.79%(95%CI 0.68-3.92)和2.91%(95%CI 1.37-5.42)。
- 调整前100天内≥3级毒性数量后,≥70岁患者进展或死亡风险是60-69岁患者的1.71倍(95%CI 1.08-2.71)。
临床怎么用
- 对≥70岁淋巴瘤患者行BEAM+AHCT前应充分评估心血管和皮肤毒性风险,并加强监测与支持治疗。
- 考虑采取干预措施以减轻毒性,同时维持移植疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose chemotherapy and autologous hematopoietic cell transplantation is an effective consolidation therapy in lymphoma; however, its use in elderly patients has been limited because of concerns for greater toxicity in this group. We investigated the toxicities of carmustine, etoposide, cytarabine, and melphalan (BEAM) and autologous hematopoietic cell transplantation (AHCT) in 346 patients in 2 age groups: 279 patients aged 60 to 69 years and 67 patients aged ≥70 years. The majority developed severe toxicities; the most common were febrile neutropenia, gastrointestinal, infections, and cardiovascular. Older patients were at higher risk for grade ≥3 cardiovascular toxicities (hazard ratio [HR], 3.36; 95% confidence interval [CI], 2.25-5.00; P < .001) and skin toxicities (HR, 2.45; 95% CI, 1.08-5.54, P = .032). In the older group, nonrelapse mortality at 100 days and at 2 years was 2.99% (95% CI, 0.55-9.32) and 6.2% (95% CI, 1.97-13.95), respectively, vs 1.79% (95% CI, 0.68-3.92) and 2.91% (95% CI, 1.37-5.42), respectively, in the younger group. When adjusting for the number of grade ≥3 toxicities within the first 100 days, older patients had a 1.71-fold (95% CI, 1.08-2.71) increased risk for progression or death relative to younger patients. Although BEAM followed by AHCT is effective, it is associated with significant organ toxicities, especially in patients aged ≥70 years. Interventions to mitigate toxicities while maintaining efficacy are much needed.
引用
- Dahi PB, Lee J, Devlin SM, et al. Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. Blood Adv. 2021. PMID: 34152404. doi:10.1182/bloodadvances.2020004167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。